Trial
NCT01160926
Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
The Christie NHS Foundation Trust
Collaborators
Cancer Research UK; AstraZeneca
Condition
Rectal Cancer
Intervention
AZD6244
Why stopped
2 DLTs had been reported from first 4 patients on lowest possible dose cohort.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-24